Jonathan Zalevsky - 16 Dec 2021 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Chief R&D Officer
Signature
Mark A. Wilson, Attorney-in-Fact
Issuer symbol
NKTR
Transactions as of
16 Dec 2021
Net transactions value
$0
Form type
4
Filing time
20 Dec 2021, 19:28:06 UTC
Previous filing
17 Nov 2021
Next filing
18 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Award $0 +52,950 +23% $0.000000 285,034 16 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Stock Option Award $0 +94,000 $0.000000 94,000 16 Dec 2021 Common Stock 94,000 $13.22 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service.
F2 This stock option vests over four years from the date of grant in equal monthly installments based on continued service.